Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

ClinicalTrials.gov ID: NCT01056276

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01056276. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and non-overlapping toxicities.

Study identification

NCT ID: NCT01056276
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: SCRI Development Innovations, LLC; Other
Enrollment: 59 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 2010 (Type not available)
Primary completion: Aug 2015 (Actual)
Completion: Feb 2017 (Actual)
Last update posted: May 3, 2017

2010 – 2017

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Los Robles Hospital and Medical Center	Thousand Oaks	California	91360	—
Florida Cancer Specialists	Fort Myers	Florida	33916	—
Hematology Oncology Clinic, LLP	Baton Rouge	Louisiana	70809	—
Center for Cancer and Blood Disorders	Bethesda	Maryland	20817	—
National Capital Clinical Research Consortium	Bethesda	Maryland	20817	—
Grand Rapids Clinical Oncology Program	Grand Rapids	Michigan	49503	—
Oncology Hematology Care Inc.	Cincinnati	Ohio	45242	—
South Carolina Oncology Associates	Columbia	South Carolina	29210	—
Chattanooga Oncology Hematology Associates	Chattanooga	Tennessee	37404	—
Tennessee Oncology	Nashville	Tennessee	37203	—
Leading Edge Research, PA	Arlington	Texas	75213	—
The Center for Cancer and Blood Disorders	Fort Worth	Texas	76104	—
Peninsula Cancer Institute	Newport News	Virginia	23601	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01056276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 3, 2017 · Synced Nov 14, 2026